作者: John L. Marshall , Robert J. Hoyer , Mary Ann Toomey , Kristen Faraguna , Ping Chang
DOI: 10.1200/JCO.2000.18.23.3964
关键词: Immunotherapy 、 Virology 、 Tumor antigen 、 Medicine 、 Active immunization 、 Recombinant virus 、 Interferon-gamma production 、 Carcinoembryonic antigen 、 Vaccinia 、 Orthopoxvirus 、 Immunology
摘要: PURPOSE: This trial sought to determine, for the first time, validity in human vaccinations of using two different recombinant vaccines diversified prime-and-boost regimens enhance T-cell responses a tumor antigen. PATIENTS AND METHODS: Eighteen patients with advanced tumors expressing carcinoembryonic antigen (CEA) were randomized receive either vaccinia (rV)-CEA followed by three avipox-CEA vaccinations, or (three times) one rV-CEA vaccination. Subsequent both cohorts avipox-CEA. Immunologic monitoring was performed CEA peptide and enzyme-linked immunospot assay interferon gamma production. RESULTS: superior reverse order generation CEA-specific responses. Further increases precursors seen when local granulocyte-macrophage colony-stimulating factor (GM-CSF) low-dose interleukin (IL)-2 given subsequent vaccinations...